Industry / Germany
G-BA's Decision Not To Reimburse Plavix Will Stand
April 2008 | Industry NewsGermany's Federal Joint Committee on Healthcare (G-BA) has confirmed that it will not reimburse Plavix (clopidogrel) as a prophylactic treatment for cardiovascular disease. The decision comes as a result of findings by the Institute for Quality and Efficiency in Healthcare (IQWiG) in 2007 that Plavix had no real benefit over Aspirin when used as secondary
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
